Screening

On June 17, 2025, the UK National Screening Committee (UK NSC) opened a public consultation on the updated evidence review regarding population screening for dementia in adults. The 2025 review concludes that there is still insufficient evidence to support the introduction of a national screening programme. Stakeholders are invited to submit comments by September 9, 2025.

On June 10, 2025, the Swiss Federal Office of Public Health published updates to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The changes will take effect on July 1, 2025, and relate to colorectal cancer screening with the increase in the number of reimbursed colonoscopies, cancer treatment, men’s health, medical aids, and other medical services.

In May 2025, the National Institute for Health and Care Research (NIHR) in England released five Med Tech-related assessments in its HTA Journal, which concerned the evaluation of high-flow nasal cannula therapy in pediatric critical care, assessment of IVD tests for guidance of antibiotic treatment, and the results of the research on clinical and cost-effectiveness of first-trimester ultrasound screening for fetal anomalies. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS, and informs NICE guidance.

On May 13, 2025, the Common Package of Benefits of the Spanish National Health System (NHS) was amended. The med tech-related updates mostly concerned in-vitro diagnostics, gastrointestinal, e-Health, cardiovascular, ENT, ophthalmology, oral health, and neurology fields.

In March 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned the results of the studies provided within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance.

On March 19, 2025, the NHS Innovation Accelerator (NIA) announced 28 new innovators (“Fellows”) with healthcare solutions awarded to join the program in 2025. NIA provides intensive, tailored support to proven healthcare solutions, helping to accelerate their adoption and maximize their impact across the NHS. Awarded innovations concern e-Health, in-vitro diagnostic, gynecology, neuromodulation, and sustainability.

In February 2025, the Ministry of Health and Care Services published a National Cancer Strategy for 2025-2030. The strategy outlines five key target areas with corresponding goals and actions. The target areas comprise pioneering cancer prevention and early detection, improving patient outcomes, enhancing user-oriented cancer care, increasing survival rates and longevity, and ensuring the best possible quality of life. The actions include the expansion of national screening initiatives, the accreditation of Comprehensive Cancer Centers, digital home monitoring, precision diagnostics, and the establishment of a national healthcare innovation hub.

In December 2024, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced changes in the cervical cancer screening program starting from January 1, 2025. The key change is that in people aged 30 to 64 years, an HPV (Human Papillomavirus) test will be the primary for cervical cancer screening instead of a cytological examination. For this age group, HPV tests will be reimbursed every five years.

On November 28, 2024, the updated version of the Finnish Laboratory Tests Nomenclature was published by the Finnish Institute for Health and Welfare (THL) to come into force on January 1, 2025. Six new codes were introduced.

On December 4, 2024, the UK National Screening Committee (UK NSC) launched a consultation on whether to offer human papillomavirus (HPV) self-sampling option to under-screened people in the cervical cancer screening program alongside traditional clinician-collected sampling by a nurse or doctor. The deadline for comments submission is February 26, 2025.

On December 2, 2024, the Swiss Federal Office of Public Health published the changes that will occur to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The updates will enter into force on January 1, 2025, and they relate to the list of explicitly evaluated services (Annex 1 of KLV/OPre), outpatient-before-hospital services (Annex 1a), List of Tools and Equipment (Annex 2), and the List of Analyses (Annex 3).

In late October 2024, the Agency for Health Technology Assessment and Tariff System (AOTMiT) published several recommendations concerning the Prenatal Testing Program, specifically on removing alpha-fetoprotein and estriol testing and qualifying the placental growth factor (PlGF) test and free fetal DNA testing (cffDNA) as part of non-invasive prenatal diagnostics.